Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia
Identifieur interne : 000047 ( PascalFrancis/Curation ); précédent : 000046; suivant : 000048Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia
Auteurs : J. M. Van Kampen [Canada] ; A. J. Stoessl [Canada]Source :
- Neuroscience [ 0306-4522 ] ; 2000.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Dyskinesias are abnormal involuntary movements which develop as a side-effect of long-term treatment with levodopa in patients with Parkinson's disease. The pathophysiology underlying these dyskinesias remains unclear, although, it has been suggested that heightened activity of dopamine D1 receptor-bearing striatonigral neurons may play a key role. Chronic pulsatile levodopa administration to hemiparkinsonian rats results in sensitization of rotational responses to apomorphine. This sensitization is thought to be analogous to levodopa-induced dyskinesias in humans. In these studies, we further clarify the role of the dopamine D1A receptor in this rodent model of levodopa-induced dyskinesias using an in vivo oligonucleotide antisense approach. Hemiparkinsonian rats received twice daily injections of levodopa for three weeks followed by intrastriatal infusion of dopamine D1A receptor antisense (7 nmol/day, three days), a scrambled missense control sequence, or saline. Those animals treated with antisense displayed significantly fewer apomorphine-induced rotations than saline- or missense-treated controls. By reducing dopamine D1A receptor expression, we were able to attenuate sensitization of the response to apomorphine resulting from chronic pulsatile levodopa treatment. Thus, the dopamine D1A receptor appears to play a significant role in levodopa-induced dyskinesias and warrants further examination. These findings may have important implications for the development of selective treatment strategies designed to alleviate parkinsonian symptoms, while minimizing motor complications.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C77
Links to Exploration step
Pascal:00-0396300Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of oligonucleotide antisense to dopamine D<sub>1A</sub> receptor messenger RNA in a rodent model of levodopa-induced dyskinesia</title><author><name sortKey="Van Kampen, J M" sort="Van Kampen, J M" uniqKey="Van Kampen J" first="J. M." last="Van Kampen">J. M. Van Kampen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, 2221 Wesbrook Mall</s1><s2>Vancouver, B.C., V6T 2B5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, 2221 Wesbrook Mall</s1><s2>Vancouver, B.C., V6T 2B5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">00-0396300</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 00-0396300 INIST</idno><idno type="RBID">Pascal:00-0396300</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C77</idno><idno type="wicri:Area/PascalFrancis/Curation">000047</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of oligonucleotide antisense to dopamine D<sub>1A</sub> receptor messenger RNA in a rodent model of levodopa-induced dyskinesia</title><author><name sortKey="Van Kampen, J M" sort="Van Kampen, J M" uniqKey="Van Kampen J" first="J. M." last="Van Kampen">J. M. Van Kampen</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, 2221 Wesbrook Mall</s1><s2>Vancouver, B.C., V6T 2B5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, 2221 Wesbrook Mall</s1><s2>Vancouver, B.C., V6T 2B5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author></analytic><series><title level="j" type="main">Neuroscience</title><title level="j" type="abbreviated">Neuroscience</title><idno type="ISSN">0306-4522</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neuroscience</title><title level="j" type="abbreviated">Neuroscience</title><idno type="ISSN">0306-4522</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term><term>Antiparkinson agent</term><term>Antisense DNA</term><term>Dopamine receptor</term><term>Dyskinesia</term><term>Levodopa</term><term>Messenger RNA</term><term>Rat</term><term>Toxicity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>DNA antisens</term><term>RNA messager</term><term>Récepteur dopaminergique</term><term>Modèle animal</term><term>Dyskinésie</term><term>Lévodopa</term><term>Toxicité</term><term>Antiparkinsonien</term><term>Rat</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesias are abnormal involuntary movements which develop as a side-effect of long-term treatment with levodopa in patients with Parkinson's disease. The pathophysiology underlying these dyskinesias remains unclear, although, it has been suggested that heightened activity of dopamine D<sub>1</sub> receptor-bearing striatonigral neurons may play a key role. Chronic pulsatile levodopa administration to hemiparkinsonian rats results in sensitization of rotational responses to apomorphine. This sensitization is thought to be analogous to levodopa-induced dyskinesias in humans. In these studies, we further clarify the role of the dopamine D<sub>1A</sub> receptor in this rodent model of levodopa-induced dyskinesias using an in vivo oligonucleotide antisense approach. Hemiparkinsonian rats received twice daily injections of levodopa for three weeks followed by intrastriatal infusion of dopamine D<sub>1A</sub> receptor antisense (7 nmol/day, three days), a scrambled missense control sequence, or saline. Those animals treated with antisense displayed significantly fewer apomorphine-induced rotations than saline- or missense-treated controls. By reducing dopamine D<sub>1A</sub> receptor expression, we were able to attenuate sensitization of the response to apomorphine resulting from chronic pulsatile levodopa treatment. Thus, the dopamine D<sub>1A</sub> receptor appears to play a significant role in levodopa-induced dyskinesias and warrants further examination. These findings may have important implications for the development of selective treatment strategies designed to alleviate parkinsonian symptoms, while minimizing motor complications.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0306-4522</s0></fA01><fA02 i1="01"><s0>NRSCDN</s0></fA02><fA03 i2="1"><s0>Neuroscience</s0></fA03><fA05><s2>98</s2></fA05><fA06><s2>1</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Effects of oligonucleotide antisense to dopamine D<sub>1A</sub> receptor messenger RNA in a rodent model of levodopa-induced dyskinesia</s1></fA08><fA11 i1="01" i2="1"><s1>VAN KAMPEN (J. M.)</s1></fA11><fA11 i1="02" i2="1"><s1>STOESSL (A. J.)</s1></fA11><fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Faculty of Medicine, University of British Columbia, 2221 Wesbrook Mall</s1><s2>Vancouver, B.C., V6T 2B5</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA20><s1>61-67</s1></fA20><fA21><s1>2000</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>17194</s2><s5>354000088987520070</s5></fA43><fA44><s0>0000</s0><s1>© 2000 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>62 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>00-0396300</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Neuroscience</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Dyskinesias are abnormal involuntary movements which develop as a side-effect of long-term treatment with levodopa in patients with Parkinson's disease. The pathophysiology underlying these dyskinesias remains unclear, although, it has been suggested that heightened activity of dopamine D<sub>1</sub> receptor-bearing striatonigral neurons may play a key role. Chronic pulsatile levodopa administration to hemiparkinsonian rats results in sensitization of rotational responses to apomorphine. This sensitization is thought to be analogous to levodopa-induced dyskinesias in humans. In these studies, we further clarify the role of the dopamine D<sub>1A</sub> receptor in this rodent model of levodopa-induced dyskinesias using an in vivo oligonucleotide antisense approach. Hemiparkinsonian rats received twice daily injections of levodopa for three weeks followed by intrastriatal infusion of dopamine D<sub>1A</sub> receptor antisense (7 nmol/day, three days), a scrambled missense control sequence, or saline. Those animals treated with antisense displayed significantly fewer apomorphine-induced rotations than saline- or missense-treated controls. By reducing dopamine D<sub>1A</sub> receptor expression, we were able to attenuate sensitization of the response to apomorphine resulting from chronic pulsatile levodopa treatment. Thus, the dopamine D<sub>1A</sub> receptor appears to play a significant role in levodopa-induced dyskinesias and warrants further examination. These findings may have important implications for the development of selective treatment strategies designed to alleviate parkinsonian symptoms, while minimizing motor complications.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02U01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>DNA antisens</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Antisense DNA</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>DNA antisentido</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>RNA messager</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Messenger RNA</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>RNA mensajero</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Dopamine receptor</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Modèle animal</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Animal model</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Modelo animal</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Dyskinésie</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Dyskinesia</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Disquinesia</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Lévodopa</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Levodopa</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Levodopa</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Toxicité</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Toxicity</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Toxicidad</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Rat</s0><s5>54</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Rat</s0><s5>54</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Rata</s0><s5>54</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fN21><s1>269</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000047 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000047 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:00-0396300
|texte= Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia
}}
| This area was generated with Dilib version V0.6.29. |  |